**Name of journal: World Journal of Gastroenterology**

**ESPS Manuscript NO: 6824**

**Columns:** **TOPIC HIGHLIGHTS**

WJG 20th Anniversary Special Issues (9): Hepatitis B virus

**When to stop nucleos(t)ide analogues treatment** **for chronic hepatitis B? Durability of antiviral response**

Kang W *et al.* Durability of nucleos(t)ide analogues therapy

Wonseok Kang, Jun Yong Park

**Wonseok Kang, Jun Yong Park,** Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul 120-752, South Korea

**Wonseok Kang, Jun Yong Park,** Liver Cirrhosis Clinical Research Center, Seoul 120-752, South Korea

**Author contributions:** Kang W and Park JY contributed to the concept and design of the study, literature search, analysis and interpretation of data and drafting of the manuscript; Park JY obtained funding and supervised the study.

**Supported by** Liver Cirrhosis Clinical Research Center, in part by a grant from the Korea Healthcare Technology R and D project, Ministry of Health and Welfare, Republic of Korea No. HI10C2020, the funders had no role in preparation of the manuscript

**Correspondence to: Jun Yong Park, MD, PhD,** Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, South Korea. drpjy@yuhs.ac

**Telephone**: +82-2-22281994 **Fax**: +82-2-3936884

**Received:** October 28, 2013 **Revised:** December 13, 2013

**Accepted:** January 14, 2014

**Published online:**

**Abstract**

Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). Although current international guidelines for the management of CHB provide information regarding when to begin the antiviral therapy with NAs, there is no clear consensus on when to stop the treatment, especially for those who respond to the therapy. Hepatitis B surface antigen loss has been regarded as an ideal endpoint of oral antiviral therapy with NAs, however since this is rarely achieved, practical endpoints have been suggested by the international guidelines. Despite the stopping rules recommended by the international guidelines, whether oral antiviral therapy with NAs can be safely discontinued is of major concern. While attention has been drawn to whether antiviral treatment with NAs can be a finite therapy, there is lack of sufficient data on off-treatment durability of highly potent NAs. Based on the available evidences, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability, with relapse rates of more than 40% for both hepatitis Be antigen (HBeAg)-positive and HBeAg-negative patients. Therefore, further studies are required to accumulate data on off-treatment durability of highly potent NAs, and future studies are warranted to identify adequate predictive markers that could provide supplementary information to guide the timing of stopping NA therapy.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Chronic hepatitis B; Antiviral therapy; Nucleos(t)ide analogue; Durability; Cessation

**Core tip:** Introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). While attention has been drawn to whether antiviral treatment with NAs can be a finite therapy in patients with CHB, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability in both HBeAg-positive and HBeAg-negative patients. In the present work, we discussed the validity of current stopping rules of NA therapy and addressed areas of uncertainty in deciding the best timing to stop NA treatment.

Kang W, Park JY. When to stop nucleos(t)ide analogues treatment? Durability of antiviral response.

*World J Gastroenterol* 2013;

**Available from:**

**DOI:**

**INTRODUCTION**

Hepatitis B virus (HBV) infects more than 350 million people worldwide and is a major cause of chronic liver disease, which may eventually evolve to cirrhosis and hepatocellular carcinoma (HCC)[[1](#_ENREF_1),[2](#_ENREF_2)]. There are several host and viral factors which affect the natural course of HBV infection, and active HBV replication has been described as the key driving force for the subsequent HBV-related immune clearance that determine liver injury and progression of liver disease, implicating the importance of sustained viral suppression, or ideally, elimination of the virus[[3](#_ENREF_3)].

In recent years, introduction of nucleos(t)ide analogues (NAs) for oral antiviral therapy has dramatically improved the clinical outcome in patients with chronic hepatitis B (CHB). Although current international guidelines for the management of CHB provide information regarding when to begin the antiviral therapy with NAs, there is no clear consensus on when to stop the treatment, especially for those who respond to the therapy.

In this article, , we discuss the validity of current stopping rules of NA therapy recommended by the international guidelines by assessing the durability of antiviral response after cessation of NAs based on currently available literature. We also address areas of uncertainty in deciding the best timing to stop NA therapy.

**TREATMENT GOALS AND STOPPING RULES**

Seroclearance of hepatitis B surface antigen (HBsAg) is a condition that is most similar to complete and definitive remission status of chronic HBV infection. In this view, the international guidelines have suggested HBsAg loss as an ideal endpoint of oral antiviral therapy with NAs. However, HBsAg loss is almost negligible even after a long-term therapy[[4-7](#_ENREF_4)]. Therefore it is anticipated that most patients with CHB probably require lifelong oral antiviral treatment with NAs. The primary goals of antiviral therapy are sustained suppression of HBV replication and hepatic inflammation thereby improving long-term outcomes and prolonging patient survival by preventing the development of progressive fibrosis, cirrhosis and/or HCC[[8-10](#_ENREF_8)]. Response to treatment is assessed based on biochemical, virological, serological, as well as histological parameters. Treatment with NAs can effectively suppress HBV replication and prevent the progression of disease.

On the other hand, long-term treatment with NAs is associated with significant problems in the management of CHB. Generally, adherence to long-term therapy is an important issue in patient management, and safety of long-term NA treatment is of concern since they are primarily eliminated by the kidney[[11](#_ENREF_11)]. Financial burden of long-term NA treatment represent another important issue in the management of CHB. In this regard, international guidelines have suggested the timing of stopping antiviral NAs based on the studies demonstrating off-therapy durability of responses to NA therapy in patients with CHB (Table 1). A finite therapy would not only offer reduced financial burden and increased treatment safety but also encourage the patients to stay adherent to the treatment.

For patients with hepatitis B e antigen (HBeAg)-positive CHB, the European Association for the Study of Liver (EASL) guideline recommends HBsAg loss with or without seroconversion as an ideal finite goal of NA therapy[[9](#_ENREF_9)]. However, NA therapy-induced HBsAg seroclearance or seroconversion is only achievable in a minority of patients. Hence, the EASL guideline also provides a reasonable option that is comparable to the recommendations of the Asian Pacific Association for the Study of the Liver (APASL) and American Association of the Study of Liver Disease (AASLD) guidelines. The APASL guideline suggests that treatment can be stopped after HBeAg seroconversion with undetectable HBV DNA by a sensitive polymerase chain reaction assay for at least 12 mo[[8](#_ENREF_8)]. Likewise, the EASL and AASLD guidelines recommend that treatment can be stopped after HBeAg seroconversion with undetectable HBV DNA and an additional 6-12 mo of consolidation therapy[[9](#_ENREF_9),[10](#_ENREF_10)]

For patients with HBeAg-negative CHB, however, currently there is no clear consensus on the optimal duration of oral antiviral therapy with NAs. Both the EASL and AASLD guidelines recommend long-term NA therapy until HBsAg seroclearance has been achieved[[9](#_ENREF_9),[10](#_ENREF_10)]. On the contrary, the APASL guideline suggests that unless HBsAg seroclearance has been achieved, cessation of NA therapy can be considered after at least 2 years of treatment if HBV DNA remains undetectable on three separate occasions 6 mo apart[[8](#_ENREF_8)].

Despite the stopping rules recommended by the international guidelines, whether oral antiviral therapy with NAs can be safely discontinued is of major concern. Accordingly, many studies have been conducted to evaluate the durability of antiviral response after cessation of NAs in patients with CHB (Table 2).

**OFF-THERAPY DURABILITY OF ANTIVIRAL RESPONSE**

***HBeAg-positive patients***

Initial studies with lamivudine showed disappointing results with its antiviral durability after cessation of therapy. Although a study of 39 patients reported lamivudine-induced HBeAg seroconversion to be durable in 77% of patients[[12](#_ENREF_12)], a subsequent study of 34 HBeAg-positive CHB patients in whom lamivudine was stopped after HBeAg seroconversion showed that the cumulative relapse rate was 37.5% after 1 year and increased to 49.2% after 2 years of discontinuation[[13](#_ENREF_13)]. Similarly, Chien *et al*[[14](#_ENREF_14)] also reported that 48% of the patients relapsed after discontinuing lamivudine for 12 months. In parallel with these results, several studies from different groups showed that the off-treatment durability of lamivudine-induced HBeAg seroconversion was not sustained in a large proportion of patients, with cumulative relapse rate of more than 50% after 1 year[[15-17](#_ENREF_15)].

On the other hand, some studies have reported a higher antiviral durability after cessation of therapy. In a study of 61 patients, Ryu *et al*[[18](#_ENREF_18)] reported that the cumulative relapse rate was 15% at 6 months and 31% at 2 years after stopping lamivudine therapy. A more recent study by Lee *et al.* also showed a durable off-treatment response in 178 patients with lamivudine-induced complete response[[19](#_ENREF_19)]. In this study, the cumulative relapse rate was 15.9% at 1 year and 30.2% at 5 years. These results were supported by a more recent prospective study with 82 patients demonstrating a cumulative relapse rate of 23.4% at 6 months and 29.4% at 4 years after discontinuation of lamivudine[[20](#_ENREF_20)].

However, in a series of recent studies with various antiviral NAs the off-treatment response was shown to be not durable despite consolidation therapy after HBeAg seroconversion. A study of 132 patients who achieved HBeAg seroconversion by various NAs demonstrated an overall relapse rate of 67% despite consolidation therapy after HBeAg seroconversion [[21](#_ENREF_21)]. Moreover, a more recent study of 39 patients treated with various NAs reported that almost all (90%) patients who stopped NA therapy after achieving HBeAg seroconversion and clinical response experienced recurrent viremia despite consolidation therapy prior to discontinuation of NAs[[22](#_ENREF_22)].

To summarize, the results from these studies imply that the current guidelines of stopping NAs after achieving HBeAg seroconversion with undetectable HBV DNA do not seem to result in a durable off-treatment antiviral response in the majority of HBeAg-positive CHB patients.

***HBeAg-negative patients***

Earlier studies showed consistent results that the antiviral response was not durable in patients who stopped NA therapy even if the guideline recommendations were followed. In a small study of 15 HBeAg-negative patients who stopped lamivudine after a year of therapy, 86% of the patients developed virological and/or biochemical relapse[[23](#_ENREF_23)]. Succeeding studies with more stringent cessation criteria showed some improvements in the durability of NA-induced antiviral response, yet the results were still disappointing. In a retrospective study of 50 HBeAg-negative patients, the cumulative relapse rates at 6 months was 30% and at 18 months was 50% despite successful lamivudine treatment for 2 years followed by withdrawal[[24](#_ENREF_24)]. Moreover, several prospective studies also demonstrated that off-treatment response rates were below satisfaction. In a long-term prospective study of 50 HBeAg-negative patients who stopped lamivudine after treatment for 24 months, the cumulative relapse rate was 43.1% at 3 years after withdrawal[[25](#_ENREF_25)]. Similarly, Liu *et al*[[26](#_ENREF_26)] have also reported a cumulative relapse rate of 56.1% at 5 years after stopping lamivudine treatment.

In a series of recent studies with antiviral NAs other than lamivudine, the durability of off-treatment response was shown to be comparable to that of lamivudine treatment. A prospective cohort study of 33 HBeAg-negative patients who had been treated with adefovir for 4-5 years and monitored for 5.5 years after cessation of treatment showed an overall relapse rate of 45% during the follow-up period[[27](#_ENREF_27)]. Interestingly, among 18 of 33 patients who achieved sustained response, 13 (72%) patients showed HBsAg clearance. Of note, serum HBsAg levels at the end of treatment showed significant association with HBsAg clearance, suggesting a possible role of HBsAg quantitation for predicting the antiviral response to NA therapy.

A more recent study by Jeng *et al*[[28](#_ENREF_28)] demonstrated off-treatment durability of entecavir therapy in 95 HBeAg-negative patients using the stopping rule recommended by the APASL guideline. In this observational study, patients were treated with entecavir for a median of 721 days, and followed up for at least 12 months. The cumulative relapse rate after 1 year of stopping entecavir treatment was 45.3%.

For the patients with HBeAg-negative CHB, current data show that about half of the patients attain durable antiviral response after discontinuation of NA therapy. This is somewhat disappointing as the off-treatment durability is not satisfactory despite following the stopping rule recommended by the guideline. Therefore, further studies would be required to find adequate factors that could predict the best timing of stopping the NA therapy.

**HBSAG QUANTITATION AS A PREDICTIVE MARKER**

Current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability, with relapse rates of more than 40% for both HBeAg-positive and HBeAg-negative patients. As a result, further studies are warranted to identify adequate predictive markers that could provide supplementary information to guide the timing of stopping NA therapy.

One of the recently proposed predictive factors for HBsAg loss is serum HBsAg quantitation. Since serum HBsAg level seems to correlate with the amount of covalently closed circular DNA (cccDNA) within the infected hepatocytes[[29-31](#_ENREF_29)], serial monitoring of serum HBsAg levels during the course of antiviral therapy may provide useful information regarding off-treatment response. Clinically, low serum levels of HBsAg and HBV DNA were reported to be predictive of spontaneous HBsAg seroclearance in treatment-naïve patients[[32](#_ENREF_32)]. For HBeAg-positive patients on NA therapy, older age, high baseline ALT and HBeAg loss were reported as the predictive factors for HBsAg loss[[33](#_ENREF_33)]. Based on these findings, it has been suggested that monitoring of serum HBsAg levels along with serum HBV DNA levels may guide the timing of stopping NA therapy[[34](#_ENREF_34)]. However, the clinical significance of serum HBsAg quantitation for predicting HBsAg loss during antiviral therapy with NAs has been challenged by several studies. In a study investigating the effect of long-term entecavir or tenofovir treatment on serum HBsAg levels in CHB patients, Zoutendijk *et al*[[33](#_ENREF_33)]. reported that the predicted median time to HBsAg loss was 36 years for HBeAg-positive and 39 years for HBeAg-negative patients Moreover, another study from a French group, based on their mathematical modeling, suggested that more than 50 years of NA therapy would be required for the clearance of HBsAg[[35](#_ENREF_35)], implying that cessation of NA therapy would be almost impossible. Nevertheless, there is an increasing attention in the clinical utility of serum HBsAg quantitation, and further studies are needed to validate its role for monitoring the antiviral response and predicting the off-treatment durability.

**CONCLUSION**

For the minority who have achieved the ultimate goal of NA therapy, *i.e.* HBsAg loss, the treatment may be discontinued. However, loss of HBsAg does not necessarily indicate complete eradication of the virus as cccDNA persists within the infected hepatocytes, and thus there is still a risk of developing HCC[[36](#_ENREF_36),[37](#_ENREF_37)]. Therefore, long-term surveillance for HCC would be mandatory albeit successful achievement of HBsAg loss and discontinuation of NA therapy.

In addition, for patients with liver cirrhosis, it would be beneficial to maintain than to discontinue NA therapy. This is supported by an increasing data that long-term viral suppression with NA therapy not only decreases hepatic inflammation but also induces regression of cirrhosis which may translate to improved clinical outcome[[38-43](#_ENREF_38)].

In conclusion, while attention has been drawn to whether antiviral treatment with NAs can be a finite therapy, there is lack of sufficient data on off-treatment durability of highly potent NAs, particularly tenofovir, and based on the available evidences, current guidelines for stopping NA therapy seems to be inadequate in terms of off-treatment durability. Therefore, further studies are required to accumulate data on off-treatment durability of highly potent NAs. Furthermore, search for adequate predictive markers that could provide supplementary information to guide the timing of stopping NA therapy is warranted. Clinical studies addressing this issue seems to be highly desirable in the future.

**REFERENCES**

1 **Lee WM**. Hepatitis B virus infection. *N Engl J Med* 1997; **337**: 1733-1745 [PMID: 9392700 DOI: 10.1056/NEJM199712113372406]

2 **Lavanchy D**. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. *J Viral Hepat* 2004; **11**: 97-107 [PMID: 14996343 DOI: 10.1046/j.1365-2893.2003.00487.x]

3 **Liaw YF**, Chu CM. Hepatitis B virus infection. *Lancet* 2009; **373**: 582-592 [PMID: 19217993 DOI: 10.1016/S0140-6736(09)60207-5]

4 **Dienstag JL**, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. *N Engl J Med* 1999; **341**: 1256-1263 [PMID: 10528035 DOI: 10.1056/NEJM199910213411702]

5 **Chang TT**, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. *N Engl J Med* 2006; **354**: 1001-1010 [PMID: 16525137 DOI: 10.1056/NEJMoa051285]

6 **Lai CL**, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. *N Engl J Med* 2007; **357**: 2576-2588 [PMID: 18094378 DOI: 10.1056/NEJMoa066422]

7 **Marcellin P**, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. *N Engl J Med* 2008; **359**: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878]

8 **Liaw YF**, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CH, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano J, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatol Int* 2012; **6**: 531-561 [DOI: 10.1007/s12072-012-9365-4]

9 **European Association For The Study Of The Liver**. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. *J Hepatol* 2012; **57**: 167-185 [PMID: 22436845 DOI: 10.1016/j.jhep.2012.02.010]

10 **Lok AS**, McMahon BJ. Chronic hepatitis B: update 2009. *Hepatology* 2009; **50**: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]

11 **Ridruejo E**, Silva MO. Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. *Expert Opin Drug Saf* 2012; **11**: 357-360 [PMID: 22417072 DOI: 10.1517/14740338.2012.672972]

12 **Dienstag JL**, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. Durability of serologic response after lamivudine treatment of chronic hepatitis B. *Hepatology* 2003; **37**: 748-755 [PMID: 12668966 DOI: 10.1053/jhep.2003.50117]

13 **Song BC**, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. *Hepatology* 2000; **32**: 803-806 [PMID: 11003626 DOI: 10.1053/jhep.2000.16665]

14 **Chien RN**, Yeh CT, Tsai SL, Chu CM, Liaw YF. Determinants for sustained HBeAg response to lamivudine therapy. *Hepatology* 2003; **38**: 1267-1273 [PMID: 14578866 DOI: 10.1053/jhep.2003.50458]

15 **van Nunen AB**, Hansen BE, Suh DJ, Löhr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. *Gut* 2003; **52**: 420-424 [PMID: 12584227]

16 **Byun KS**, Kwon OS, Kim JH, Yim HJ, Chang YJ, Kim JY, Yeon JE, Park JJ, Kim JS, Bak YT, Lee CH. Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy. *J Gastroenterol Hepatol* 2005; **20**: 1838-1842 [PMID: 16336441 DOI: 10.1111/j.1440-1746.2005.03952.x]

17 **Yoon SK**, Jang JW, Kim CW, Bae SH, Choi JY, Choi SW, Lee YS, Lee CD, Chung KW, Sun HS, Kim BS. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. *Intervirology* 2005; **48**: 341-349 [PMID: 16024938 DOI: 10.1159/000086061]

18 **Ryu SH**, Chung YH, Choi MH, Kim JA, Shin JW, Jang MK, Park NH, Lee HC, Lee YS, Suh DJ. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study. *J Hepatol* 2003; **39**: 614-619 [PMID: 12971973]

19 **Lee HW**, Lee HJ, Hwang JS, Sohn JH, Jang JY, Han KJ, Park JY, Kim do Y, Ahn SH, Paik YH, Lee CK, Lee KS, Chon CY, Han KH. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. *Hepatology* 2010; **51**: 415-421 [PMID: 19902424 DOI: 10.1002/hep.23323]

20 **Wang L**, Liu F, Liu YD, Li XY, Wang JB, Zhang ZH, Wang YZ. Stringent cessation criterion results in better durability of lamivudine treatment: a prospective clinical study in hepatitis B e antigen-positive chronic hepatitis B patients. *J Viral Hepat* 2010; **17**: 298-304 [PMID: 19758278 DOI: 10.1111/j.1365-2893.2009.01178.x]

21 **Reijnders JG**, Perquin MJ, Zhang N, Hansen BE, Janssen HL. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. *Gastroenterology* 2010; **139**: 491-498 [PMID: 20381492 DOI: 10.1053/j.gastro.2010.03.059]

22 **Chaung KT**, Ha NB, Trinh HN, Garcia RT, Nguyen HA, Nguyen KK, Garcia G, Ahmed A, Keeffe EB, Nguyen MH. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. *J Clin Gastroenterol* 2012; **46**: 865-870 [PMID: 22941429 DOI: 10.1097/MCG.0b013e31825ceed9]

23 **Santantonio T**, Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. *J Hepatol* 2000; **32**: 300-306 [PMID: 10707871]

24 **Fung SK**, Wong F, Hussain M, Lok AS. Sustained response after a 2-year course of lamivudine treatment of hepatitis B e antigen-negative chronic hepatitis B. *J Viral Hepat* 2004; **11**: 432-438 [PMID: 15357648 DOI: 10.1111/j.1365-2893.2004.00556.x]

25 **Paik YH**, Kim JK, Kim do Y, Park JY, Ahn SH, Han KH, Chon CY, Lee KS. Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. *J Korean Med Sci* 2010; **25**: 882-887 [PMID: 20514309 DOI: 10.3346/jkms.2010.25.6.882]

26 **Liu F**, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. *J Gastroenterol Hepatol* 2011; **26**: 456-460 [PMID: 21332542 DOI: 10.1111/j.1440-1746.2010.06492.x]

27 **Hadziyannis SJ**, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. *Gastroenterology* 2012; **143**: 629-36.e1 [PMID: 22659218 DOI: 10.1053/j.gastro.2012.05.039]

28 **Jeng WJ**, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, Liaw YF. Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. *Hepatology* 2013; **58**: 1888-1896 [PMID: 23744454 DOI: 10.1002/hep.26549]

29 **Chan HL**, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, Wong GL, Sung JJ. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. *Clin Gastroenterol Hepatol* 2007; **5**: 1462-1468 [PMID: 18054753 DOI: 10.1016/j.cgh.2007.09.005]

30 **Thompson AJ**, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, Slavin J, Bowden S, Gane EJ, Abbott W, Lau GK, Lewin SR, Visvanathan K, Desmond PV, Locarnini SA. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. *Hepatology* 2010; **51**: 1933-1944 [PMID: 20512987 DOI: 10.1002/hep.23571]

31 **Lee JM**, Ahn SH. Quantification of HBsAg: basic virology for clinical practice. *World J Gastroenterol* 2011; **17**: 283-289 [PMID: 21253386 DOI: 10.3748/wjg.v17.i3.283]

32 **Liu J**, Lee MH, Batrla-Utermann R, Jen CL, Iloeje UH, Lu SN, Wang LY, You SL, Hsiao CK, Yang HI, Chen CJ. A predictive scoring system for the seroclearance of HBsAg in HBeAg-seronegative chronic hepatitis B patients with genotype B or C infection. *J Hepatol* 2013; **58**: 853-860 [PMID: 23246508 DOI: 10.1016/j.jhep.2012.12.006]

33 **Zoutendijk R**, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. *J Infect Dis* 2011; **204**: 415-418 [PMID: 21742840 DOI: 10.1093/infdis/jir282]

34 **Chan HL**, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. *Antivir Ther* 2011; **16**: 1249-1257 [PMID: 22155906 DOI: 10.3851/IMP1921]

35 **Chevaliez S**, Hézode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. *J Hepatol* 2013; **58**: 676-683 [PMID: 23219442 DOI: 10.1016/j.jhep.2012.11.039]

36 **Ahn SH**, Park YN, Park JY, Chang HY, Lee JM, Shin JE, Han KH, Park C, Moon YM, Chon CY. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. *J Hepatol* 2005; **42**: 188-194 [PMID: 15664243 DOI: 10.1016/j.jhep.2004.10.026]

37 **Papatheodoridis GV**, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. *Gut* 2011; **60**: 1109-1116 [PMID: 21270118 DOI: 10.1136/gut.2010.221846]

38 **Dienstag JL**, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. *Gastroenterology* 2003; **124**: 105-117 [PMID: 12512035 DOI: 10.1053/gast.2003.50013]

39 **Malekzadeh R**, Mohamadnejad M, Rakhshani N, Nasseri-Moghaddam S, Merat S, Tavangar SM, Sohrabpour AA. Reversibility of cirrhosis in chronic hepatitis B. *Clin Gastroenterol Hepatol* 2004; **2**: 344-347 [PMID: 15067631]

40 **Hadziyannis SJ**, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. *Gastroenterology* 2006; **131**: 1743-1751 [PMID: 17087951 DOI: 10.1053/j.gastro.2006.09.020]

41 **Chang TT**, Liaw YF, Wu SS, Schiff E, Han KH, Lai CL, Safadi R, Lee SS, Halota W, Goodman Z, Chi YC, Zhang H, Hindes R, Iloeje U, Beebe S, Kreter B. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. *Hepatology* 2010; **52**: 886-893 [PMID: 20683932 DOI: 10.1002/hep.23785]

42 **Schiff ER**, Lee SS, Chao YC, Kew Yoon S, Bessone F, Wu SS, Kryczka W, Lurie Y, Gadano A, Kitis G, Beebe S, Xu D, Tang H, Iloeje U. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. *Clin Gastroenterol Hepatol* 2011; **9**: 274-276 [PMID: 21145419 DOI: 10.1016/j.cgh.2010.11.040]

43 **Marcellin P**, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. *Lancet* 2013; **381**: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1]

44 **Fung J**, Lai CL, Tanaka Y, Mizokami M, Yuen J, Wong DK, Yuen MF. The duration of lamivudine therapy for chronic hepatitis B: cessation vs. continuation of treatment after HBeAg seroconversion. *Am J Gastroenterol* 2009; 104: 1940-1946; quiz 1947 [PMID: 19455108 DOI:10.1038/ajg.2009.200]

45 **Chien RN**, Liaw YF. Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. *Antivir Ther* 2006; 11: 947-952 [PMID: 17302259]

46 **Chan HL**, Wang H, Niu J, Chim AM, Sung JJ. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial. *Antivir Ther* 2007; 12: 345-353 [PMID: 17591024]

47 **Shouval D**, Lai CL, Chang TT, Cheinquer H, Martin P, Carosi G, Han S, Kaymakoglu S, Tamez R, Yang J, Tenney D, Brett-Smith H. Relapse of hepatitis B in HBeAg-negative chronic hepatitis B patients who discontinued successful entecavir treatment: the case for continuous antiviral therapy. *J Hepatol* 2009; 50: 289-295 [PMID: 19070393 DOI:10.1016/j.jhep.2008.10.017]

48 **Paik YH**, Kim JK, Kim do Y, Park JY, Ahn SH, Han KH, Chon CY, Lee KS. Clinical efficacy of a 24-months course of lamivudine therapy in patients with HBeAg negative chronic hepatitis B: a long-term prospective study. *J Korean Med Sci* 2010; 25: 882-887 [PMID:20514309 DOI:10.3346/jkms.2010.25.6.882]

49 **Liu F**, Wang L, Li XY, Liu YD, Wang JB, Zhang ZH, Wang YZ. Poor durability of lamivudine effectiveness despite stringent cessation criteria: a prospective clinical study in hepatitis B e antigen-negative chronic hepatitis B patients. *J Gastroenterol Hepatol* 2011; 26: 456-460 [PMID: 21332542 DOI: 10.1111/j.1440-1746.2010.06492.x]

50 **Hadziyannis SJ**, Sevastianos V, Rapti I, Vassilopoulos D, Hadziyannis E. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. *Gastroenterology* 2012; 143: 629-636 e621 [PMID: 22659218 DOI:10.1053/j.gastro.2012.05.039]

51 **Kim YJ**, Kim K, Hwang SH, Kim SS, Lee D, Cheong JY, Cho SW. Durability after discontinuation of nucleos(t)ide therapy in chronic HBeAg negative hepatitis patients. *Clin Mol Hepatol* 2013; 19: 300-304 [PMID: 24133668 DOI: 10.3350/cmh.2013.19.3.300]

**P-Reviewers:** Abaalkhail FA, Niu ZS **S-Editor:** Qi Y

**L-Editor: E-Editor:**

**Table 1** **Criteria for stopping nucleos(t)ide analogue therapy in chronic hepatitis B patients**

|  |  |  |  |
| --- | --- | --- | --- |
| 　 | **HBeAg-positive chronic hepatitis B** |  | **HBeAg-negative chronic hepatitis B** |
| APASL 2012 | HBeAg seroconversion with undetectable HBV DNA for at least 12 mo |  | HBsAg seroclearance orNA therapy > 2 yr and undetectable HBV DNA on three separate occasions, 6 months apart |
|  |  |  |  |
| EASL 2012 | HBsAg seroclearance orHBeAg seroconversion with undetectable HBV DNA and 12 mo of consolidation therapy |  | HBsAg seroclearance |
|  |  |  |  |
| AASLD 2009 | HBeAg seroconversion with undetectable HBV DNA and > 6 mo of consolidation therapy |  | HBsAg seroclearance |
| 　 | 　 | 　 | 　 |
| HBeAg: Hepatitis Be antigen; APASL: Asian Pacific Association for the Study of the Liver; EASL: European Association for the Study of Liver; AASLD: American Association of the Study of Liver Disease. |

.

**Table 2 Off-therapy durability of response to nucleos(t)ide analogue therapy in chronic hepatitis B patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Ref.** | **NA**  | ***n*** |  | **Treatment duration** | **Cumulative relapse rate** |
| HBeAg-positive CHB |
|  | Song *et al*[13]  | LMV | 98 |  | 10.3 ± 3.1 mo | 1 yr, 37.5%; 2 yr 49.2% |
|  | Chien *et al*[14] | LMV | 82 |  | 16 (3-55) mo | 48%1 |
|  | Dienstag *et al*[12]  | LMV | 39 |  | 36.6 (4.8-45.6) mo | 77%1 |
|  | Ryu *et al*[18] | LMV | 61 |  |  | 6 mo, 15%; 1 yr, 21%; 2 yr, 31% |
|  | van Nunen *et al*[15]  | LMV | 59 |  |  | 3 yr, 54% |
|  | Byun *et al*[16]  | LMV | 132 |  | 14 ± 7 mo | 6 mo, 58%; 1 yr, 66% |
|  | Yoon *et al*[17] | LMV | 95 |  | 26 mo | 1 yr, 52%; 2 yr, 55.7% |
|  | Fung *et al*[44]  | LMV | 22 |  | 23 (5-91) mo | 44%1 |
|  | Lee *et al*[19]  | LMV | 178 |  | 26 (12-77) mo | 1 yr, 15.9%; 5 yr, 30.2% |
|  | Reijnders *et al*[21]  | Various | 132 |  | 26 (16-43) mo | 67%1 |
|  | Wang *et al*[20]  | LMV | 82 |  | 24 (12-54) mo | 1 yr, 23.4%; 2 yr, 25.0%; 4 yr, 29.4% |
|  | Chaung *et al*[22]  | Various | 39 |  |  | 90%1 |
|  |  |  |  |  |  |  |
| HBeAg-negative CHB |
|  | Santantonio *et al*[23]  | LMV | 15 |  | 52 wk | 74%1 |
|  | Fung *et al*[24]  | LMV | 50 |  | 2 yr | 6 mo, 30%; 12 mo, 50%; 18 mo, 50% |
|  | Chien *et al*[45]  | LMV | 85 |  | 7.4 (6-12) mo | 61%1 |
|  | Chan *et al*[46]  | LMV | 139 |  | 24 mo | 90%1 |
|  | Shouval *et al*[47] | ETV | 257 |  | 48 wk | 3%1 |
|  |  | LMV | 201 |  | 48 wk | 5%1 |
|  | Paik *et al*[48]  | LMV | 50 |  | 24 mo | 1 yr, 20.9%; 2 yr, 36.0%; 3 yr, 43.1% |
|  | Liu *et al*[49]  | LMV | 61 |  | ≥ 24 mo | 6 mo, 26.2%; 1 yr, 43.6%; 5 yr, 56.1% |
|  | Hadziyannis *et al*[50]  | ADV | 33 |  | ≥ 4 yr | 45%1 |
|  | Jeng *et al*[28]  | ETV | 95 |  | 721 (395-1762) d | 1 yr, 45.3% |
|  | Kim *et al*[51] | Various | 45 |  |  | 6 mo, 48.9%; 1 yr, 73.3% |
| 　 | 　 | 　 | 　 | 　 | 　 | 　 |

1Overall relapse. NA: Nucleos(t)ide analogue; CHB: Chronic hepatitis B; LMV: Lamivudine; ETV: Entecavir; ADV: Adefovir dipivoxil.